Vaxcyte, Inc (PCVX) September 105 puts active as share price up 37%
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Oil prices jump 4% as fresh US-Iran fighting stokes supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- Dell again lifts annual forecasts as AI demand powers record results
- Fed’s Barr backs rate hike if inflation fails to cool, September odds hit 66%
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Gap taps Coach architect Reed Krakoff for $29.95-$498 handbag line
- Comstock Resources signs $1.65B deal with SOCAR, $450M JV
Vaxcyte (PCVX) PT Raised to $140 at BofA Securities
September 4, 2024 5:27 AM EDTBofA Securities analyst Jason Gerberry raised the price target on Vaxcyte (NASDAQ: PCVX) to $140.00 (from $101.00) while maintaining a Buy rating.
The analyst comments "Vaxcyte shares are up (+35%) on announced positive Ph1/2 results for VAX-31, a pneumococcal vaccine tested in... More
TD Cowen Reiterates Buy Rating on Vaxcyte (PCVX)
September 3, 2024 4:10 PM EDTTD Cowen analyst Tara Bancroft reiterated a Buy rating on Vaxcyte (NASDAQ: PCVX).
The analyst comments "Recall that VAX-31 is a 31-valent pneumococcal conjugate vaccine (PCV) developed to expand coverage to over 95% of circulating invasive pneumococcal disease (IPD) in the US (and 98% in the EU). For reference, Pfizer's Prevnar 20 (PCV20, 20-valent and currently the market leader) only covers 52%, and Merck's more recently approved V116 (PCV21; 21-valent and recommended on parity with PCV20 here) only covers 83%. In the... More
